We are live on ! Find out more
AVLSA

Atlas Venture Life Science Advisors Portfolio holdings

AUM $790M
1-Year Est. Return 223.66%
This Fund
S&P 500
This Quarter Est. Return
+0.25%
1 Year Est. Return
+223.66%
3 Year Est. Return
+485.32%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$598M
AUM Growth
-$193M
Cap. Flow
+$167K
Cap. Flow %
0.03%
Top 10 Hldgs %
96.33%
Holding
17
New
–
Increased
1
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
DAWN
Day One Biopharmaceuticals
DAWN
+$7.92M

Top Sells

Rank Stock Value
1
JBIO
Jade Biosciences
JBIO
+$6.35M
2
COGT icon
Cogent Biosciences
COGT
+$1.4M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DAWN
1
DELISTED
Day One Biopharmaceuticals
DAWN
$161M 26.84%
8,968,305
+766,667
+9% +$7.92M
KYMR icon
2
Kymera Therapeutics
KYMR
$8.51B
$135M 22.63%
6,875,698
– –
DYN icon
3
Dyne Therapeutics
DYN
$4.7B
$61.4M 10.26%
8,934,902
– –
REPL icon
4
Replimune Group
REPL
$941M
$56.1M 9.38%
3,209,627
– –
GBIO
5
DELISTED
Generation Bio
GBIO
$54.3M 9.08%
827,888
– –
JBIO
6
Jade Biosciences
JBIO
$1.2B
$41.2M 6.89%
75,380
-13,302
-15% -$6.35M
IMA
7
ImageneBio Inc
IMA
$63M
$22.2M 3.72%
418,182
– –
AKRO
8
DELISTED
Akero Therapeutics
AKRO
$21.1M 3.53%
2,232,251
– –
VIGL
9
DELISTED
Vigil Neuroscience
VIGL
$15.1M 2.52%
5,836,874
– –
IRON icon
10
Disc Medicine
IRON
$2.94B
$8.88M 1.48%
175,146
– –
XLO icon
11
Xilio Therapeutics
XLO
$59.9M
$8.06M 1.35%
197,096
– –
DNTH icon
12
Dianthus Therapeutics
DNTH
$5.84B
$4.17M 0.7%
217,284
– –
TECX
13
Tectonic Therapeutic
TECX
$529M
$4.16M 0.7%
376,739
– –
FSTX
14
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$3.75M 0.63%
599,524
– –
VRDN icon
15
Viridian Therapeutics
VRDN
$2.09B
$1.04M 0.17%
90,072
– –
SPRO icon
16
Spero Therapeutics
SPRO
$67.7M
$764K 0.13%
1,031,160
– –
COGT icon
17
Cogent Biosciences
COGT
$6.65B
– –
-186,487
Closed -$1.4M

Similar funds

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
AT
Avenir Tech Hong Kong $790M AUM 17.91% 1-Year Est. Return
MTWSIF
Mivtachim The Workers Social Insurance Fund Tel Aviv, Israel $789M AUM 73.25% 1-Year Est. Return
VH
V3 Holding Rye, New York $789M AUM 459.57% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
AI
Aperture Investors New York $791M AUM 54.66% 1-Year Est. Return
VCM
Vision Capital Management Portland, Oregon $792M AUM 18.17% 1-Year Est. Return
SWIG
Strategic Wealth Investment Group Louisville, Kentucky $788M AUM 14.6% 1-Year Est. Return

Atlas Venture Life Science Advisors's Q2 2022 Portfolio in Review

As of Q2 2022, Atlas Venture Life Science Advisors held 17 positions worth $598M, down 24% from $791M the previous quarter. Its ten largest holdings account for 96% of the portfolio.

Atlas Venture Life Science Advisors's Q2 2022 filing shows 1 increased, 1 reduced and 1 closed positions. The largest sale was Jade Biosciences, an estimated $6.35M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Atlas Venture Life Science Advisors added most to Day One Biopharmaceuticals in Q2 2022, an estimated $7.92M increase.
  • Atlas Venture Life Science Advisors's biggest Q2 2022 reduction was Jade Biosciences, cutting an estimated $6.35M.
  • Atlas Venture Life Science Advisors fully exited Cogent Biosciences in Q2 2022, selling an estimated $1.4M.
  • Atlas Venture Life Science Advisors's ten largest holdings make up 96% of its $598M portfolio in Q2 2022.
  • Atlas Venture Life Science Advisors opened 0 new positions and closed 1 in Q2 2022.
  • Atlas Venture Life Science Advisors's portfolio value fell 24% quarter-over-quarter to $598M.

Based on Atlas Venture Life Science Advisors's 13F filing for Q2 2022, filed 3 Aug 2022.